How genetic changes cause congenital dyserythropoietic anemia
The molecular pathophysiology of the congenital dyserythropoietic anemias
This project looks for genetic and cellular problems behind congenital dyserythropoietic anemia to find ways to restore healthy red blood cell production for affected adults.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11258943 on NIH RePORTER |
What this research studies
Researchers created human red blood cell precursor cells with the SEC23B defect that causes the most common type of CDA and grow them in the lab to mimic the disease. They used a genome-wide CRISPR gene knockout screen in those cells to find other genes that can rescue the poor red blood cell maturation seen in CDAII. Top hits so far include the genes LRF and miR-451, and the team will study how changing these genes affects survival and differentiation of erythroid cells. Although the work is done in human cells in the lab, the findings are directly tied to mutations found in patients and may guide future patient-focused studies.
Who could benefit from this research
Good fit: Adults with congenital dyserythropoietic anemia—especially those with CDAII or known SEC23B mutations—are the group most directly related to this research.
Not a fit: People with other types of anemia or without CDA-related genetic changes are unlikely to gain direct benefit from this specific project.
Why it matters
Potential benefit: If successful, the work could point to new targets or strategies to improve red blood cell production and reduce anemia in people with CDA.
How similar studies have performed: Previous research identified SEC23B as a cause of CDAII and early experiments show the CRISPR screen hits (like LRF and miR-451) can modify the defect, but translating these findings toward treatments is still at a preclinical stage.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Khoriaty, Rami — University of Michigan at Ann Arbor
- Study coordinator: Khoriaty, Rami
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.